Company Analysis Fulcrum Therapeutics, Inc.
1. Summary
Advantages
- Price (4.17 $) is less than fair price (6.22 $)
Disadvantages
- Dividends (0%) are below the sector average (0.5399%).
- The stock's return over the last year (-44.46%) is lower than the sector average (-37.33%).
- Current debt level 4.2% has increased over 5 years from 0.0453%.
- The company's current efficiency (ROE=-41.39%) is lower than the sector average (ROE=9.39%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Fulcrum Therapeutics, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 5.1% | -1.7% | 2% |
| 90 days | 28.4% | -40.1% | 6.2% |
| 1 year | -44.5% | -37.3% | 27% |
FULC vs Sector: Fulcrum Therapeutics, Inc. has significantly underperformed the "Healthcare" sector by -7.13% over the past year.
FULC vs Market: Fulcrum Therapeutics, Inc. has significantly underperformed the market by -71.5% over the past year.
Stable price: FULC is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: FULC with weekly volatility of -0.855% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (4.17 $) is lower than the fair price (6.22 $).
Price significantly below the fair price: The current price (4.17 $) is 49.2% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (312.5) is higher than that of the sector as a whole (61.47).
P/E vs Market: The company's P/E (312.5) is higher than that of the market as a whole (51.48).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (1.72) is lower than that of the sector as a whole (4.79).
P/BV vs Market: The company's P/BV (1.72) is lower than that of the market as a whole (3.44).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (144.48) is higher than that of the sector as a whole (33.58).
P/S vs Market: The company's P/S indicator (144.48) is higher than that of the market as a whole (10.3).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-3.6) is higher than that of the sector as a whole (-17.26).
EV/Ebitda vs Market: The company's EV/Ebitda (-3.6) is lower than that of the market as a whole (29.6).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 8.78% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (8.78%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (11.51%).
5.4. ROE
ROE vs Sector: The company's ROE (-41.39%) is lower than that of the sector as a whole (9.39%).
ROE vs Market: The company's ROE (-41.39%) is lower than that of the market as a whole (8.95%).
5.5. ROA
ROA vs Sector: The company's ROA (-37.77%) is lower than that of the sector as a whole (0.1519%).
ROA vs Market: The company's ROA (-37.77%) is lower than that of the market as a whole (6.3%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5399%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 07.05.2024 | Tourangeau Greg Principal Accounting Officer |
Sale | 7.76 | 1 831 | 236 |
| 08.03.2024 | Tourangeau Greg Vice President, Finance |
Sale | 11.72 | 57 240 | 4 884 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
